Australia markets closed

ABBV Jun 2023 240.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.10000.0000 (0.00%)
As of 01:09PM EST. Market open.
Full screen
Previous close0.1000
Open0.1000
Bid0.0000
Ask0.0000
Strike240.00
Expiry date2023-06-16
Day's range0.1000 - 0.1000
Contract rangeN/A
Volume5
Open interestN/A
  • Zacks

    AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

    AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

  • PR Newswire

    AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

    AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.

  • Motley Fool

    Is AbbVie Stock a Buy Now?

    Given the volatility of AbbVie's (NYSE: ABBV) stock over the past year, it's pretty clear that traders are worried about next year's impending Humira patent cliff. Although the way AbbVie is going, an earnings slump is likely to be short-lived. Humira was seen as a blockbuster from the beginning; the rheumatoid arthritis medication brought in $800 million in its first full year of sales in 2003, back when AbbVie was still part of Abbott Laboratories.